Research Area / Fields

  1. Polymer and macromolecular chemistry.
  2. Biomaterials science.
  3. Microwave-assisted polymer synthesis.
  4. Drug crystallization and nanocrystals.
  5. Hybrid polymer-ceramic nanobiomaterials.
  6. Colloidal chemistry (drug and polymer self-assembly).
  7. Nanomedicine (drug encapsulation, release and targeting).
  8. Therapy of poverty-related diseases (HIV, tuberculosis), cancer, intestinal diseases.
  9. Cell culture.
  10. Pharmacokinetics (oral, inhalatory and intranasal administration routes).

Short Bio

Prof. Alejandro Sosnik received a Pharmacy degree from the University of Buenos Aires (1994) and Ph.D. in applied chemistry from the The Hebrew University of Jerusalem (2003). In 2003-6, Prof. Sosnik spent a postdoctoral at the University of Toronto. Between 2006 and 2013, he was Assistant Professor at the Faculty of Pharmacy and Biochemistry (University of Buenos Aires) and Investigator of the National Science Research Council. In 2014, Prof. Sosnik was appointed Associate Professor of the Department of Materials Science and Engineering of Technion-Israel Institute of Technology where he founded the Laboratory of Pharmaceutical Nanomaterials Science and promoted to the rank of Full Professor in 2020. He is the author of over 170 peer-reviewed articles, reviews, editorials, and book chapters in biomaterials and pharmaceutical science, tissue engineering, drug delivery, and nanotechnology and co-inventor of several patents related to biomedical and pharmaceutical innovation and editor of two books.

The Laboratory of Pharmaceutical Nanomaterials Science is an expert in design, synthesis, characterization of pure drug, polymeric and hybrid ceramic/polymer and metallic/polymer nanoparticles and microparticles and pharmaceutical formulations for different therapeutic applications, including cancer, and infectious and inflammatory diseases and by different parenteral (e.g., intravenous) and non-parenteral (e.g., oral, intranasal) administration routes with an emphasis in mucosal delivery. The laboratory also develops production processes that maximize the chances of bench-to-bedside translation and biological models to screen the performance of the different therapeutic platforms in vitro as a preamble to in vivo studies in clinically relevant animal models. One area of special interest and expertise is in the investigation of the self-assembly of small molecules (e.g., drugs) and macromolecules (e.g., polymers, proteins) in physiologically relevant media and the use of self-assembled nanoparticles such as polymeric micelles and multimicellar amphiphilic nanoparticles in drug targeting and delivery.

Available Technologies for commercialization

arrow Business Development Contacts
Dr. Gal Gur
Director of Business Development, Life Sciences